Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.
Cipla is moving forward with the sale of Afrezza, an insulin patients inhale from the mouth, aiming to offer a painless alternative to injectable insulin. The big question is whether this inhaled option can gain traction against entrenched global players and established injection-based routines in diabetes care.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
